Recombinant Human VEGF-C Protein, CF

  
  • Purity
    >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
  • Endotoxin Level
    <0.10 EU per 1 μg of the protein by the LAL method.
  • Activity
    Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96:9671. The ED50 for this effect is typically 1.5-9 ng/mL.
  • Source
    Chinese Hamster Ovary cell line, CHO-derived Ala112-Arg227
  • Accession #
  • N-terminal Sequence
    Analysis
    Ala112
  • Predicted Molecular Mass
    13 kDa
  • SDS-PAGE
    13-20 kDa, reducing conditions
Carrier Free
What does CF mean?
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
9199-VC/CF
 
9199-VC
Formulation Lyophilized from a 0.2 μm filtered solution in HCl.
Formulation Lyophilized from a 0.2 μm filtered solution in HCl with BSA as a carrier protein.
Reconstitution Reconstitute at 250 μg/mL in 4 mM HCl.
Reconstitution Reconstitute at 250 μg/mL in 4 mM HCl.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Data Images
RecombinantHuman VEGF-C (Catalog # 9199-VC/CF) induces HMVEC human microvascular endothelialcell  proliferation. The ED50 for thiseffect is typically 1.5-9 ng/mL. The ED50 for the three competitors is  30 ng/mL, which is at least more than
10-fold weaker.
Background: VEGF-C
Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors (1). VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homolgy domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/Flt-4 (2-4). Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/Flk-1 (2, 4). Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis (5-8). VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes (9-12). It also induces physiological and intratumoral neoangiogenesis and vessel sprouting through interactions with VEGF R2 (8, 13, 14).
  • References:
    1. Chen, J.-C. et al. (2013) Int. J. Mol. Sci. 14:88.
    2. Joukov, V. et al. (1996) EMBO J. 15:290.
    3. Kukk, E. et al. (1996) Development 122:3829.
    4. Joukov, V. et al. (1997) EMBO J. 16:3898.
    5. Karkkainen, M. et al. (2004) Nat. Immunol. 5:74.
    6. Jeltsch, M. et al. (1997) Science 276:1423.
    7. Makinen, T. et al. (2001) Nat. Med. 7:199.
    8. Laakkonen, P. et al. (2007) Cancer Res. 67:593.
    9. Hoshida, T. et al. (2006) Cancer Res. 66:8065.
    10. Mandriota, S.J. et al. (2001) EMBO J. 20:672.
    11. Skobe, M. et al. (2001) Nat. Med. 7:192.
    12. Padera, T.P. et al. (2002) Science 296:1883.
    13. Tammela, T. et al. (2008) Nature 454:656.
    14. Cao, Y. et al. (1998) Proc. Natl. Acad. Sci. 95:14389.
  • Long Name:
    Vascular Endothelial Growth Factor C
  • Entrez Gene IDs:
    7424 (Human); 22341 (Mouse)
  • Alternate Names:
    Flt4 ligand; Flt4-L; vascular endothelial growth factor C; Vascular endothelial growth factor-related protein; VEGFC; VEGF-C; VRPFLT4 ligand DHM
Related Research Areas

Have you used Recombinant Human VEGF-C Protein, CF?

Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Order Details

  • Formulations

Contact Information

Calculators
Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷
R&D Systems Guarantee

Feedback

Customer Information